Skip to content
    Monograph Capital logo

    Monograph Capital

    London, United KingdomFounded 2021
    www.monograph.bioLinkedIn
    Biotech & Life SciencesHealthcare

    Monograph Capital is a transatlantic life sciences venture capital firm with offices in London and San Francisco. Founded in 2021 by Fred Cohen and Tim Funnell, the firm finds and funds groundbreaking life sciences companies, often co-founding companies alongside scientific innovators to translate promising science into life-changing treatments.

    56% of their portfolio is in Biotech & Life Sciences. Deal activity increased 400% year-over-year (5 deals in the last 12 months). Their most common stage is series-a (52% of deals). Average disclosed round size is $97.1M (across 26 rounds with reported amounts).

    Find people at Monograph Capital on Goldilocks AI

    Portfolio

    20

    Fund Size

    $153.7M

    Top Stage

    Series A

    Last 12 Mo

    5

    Team

    Charles Conn

    Charles Conn

    Partner, MBA, MA

    Fred Cohen

    Fred Cohen

    Partner and Chairman, MD, DPhil

    Matt McAviney

    Matt McAviney

    Partner, MBA, MD

    Mike LaGatta

    Mike LaGatta

    Partner and COO, JD, MBA, LLM

    Tim Funnell

    Tim Funnell

    Partner, DPhil, BS

    Freddie Dear

    Freddie Dear

    Principal (Portfolio), BSc

    Jaideep Dudani

    Jaideep Dudani

    Principal (Portfolio), PhD, BS

    Melisa Guven

    Melisa Guven

    Principal, PhD, MSc, BSc

    Jeremias Reich

    Jeremias Reich

    Associate, MBBS, BSc

    Michelle He

    Michelle He

    Associate, BSc

    Oscar Molina

    Oscar Molina

    Associate, PhD, BS

    BO

    Brandi O’Donnell

    Chief of Staff & EA, BA

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    27 investments
    CompanyRoundAmountDate
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJun 2026
    OOllinSeries B$330MJun 2026
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJan 2026
    Ollin Biosciences logoOllin BiosciencesSeries B$330MJan 2026
    Prolynx logoProlynxSeries A$70MDec 2025
    Elevara Medicines logoElevara MedicinesSeries A$70MOct 2025
    Elevara Medicines logoElevara MedicinesSeries A$70MSep 2025
    Ouro Medicines logoOuro MedicinesSeries A$120MJan 2025
    Maxion logoMaxionSeries A$72MJan 2025
    MMaxion Therapeutics Ltd.Series A$72MJan 2025
    Elevara Medicines logoElevara MedicinesSeries A$70MJan 2025
    Prolynx logoProlynxSeries A$70MJan 2025
    Autobahn Therapeutics logoAutobahn TherapeuticsSeries C$100MJul 2024
    Autobahn logoAutobahnSeries C$100MJul 2024
    MMaxion Therapeutics Ltd.Series A$16MFeb 2024
    Sudo Biosciences logoSudo BiosciencesSeries B$147MJan 2024
    Sudo logoSudoSeries B$147MJan 2024
    AAscend Gene Cell TherapiesSeries A$132.5MMay 2023
    ODAIA logoODAIASeries B$25MMay 2023
    RegASK logoRegASKSeries A$10MDec 2022
    MiroBio logoMiroBioSeries B$97MJan 2022
    AviadoBio logoAviadoBioSeed$16.5MDec 2021
    AviadoBio logoAviadoBioSeries A$80MJan 2021
    Nocion Therapeutics logoNocion TherapeuticsSeries B$62M—
    NNocionSeries B$62M—
    Page 1 of 2

    Top Co-Investors

    LifeArc Ventures7 shared
    Forbion5 shared
    Dementia Discovery Fund4 shared
    Frazier Life Sciences4 shared
    F-Prime Capital4 shared
    ARCH Venture Partners4 shared
    Canaan Partners4 shared
    BGF3 shared
    Solasta Ventures3 shared
    General Catalyst3 shared
    British Patient Capital3 shared
    Eli Lilly and Company3 shared
    Sofinnova Partners3 shared
    OrbiMed3 shared
    New Enterprise Associates3 shared
    UPMC Enterprises3 shared
    Frazier Healthcare Partners3 shared
    Fidelity Investments3 shared
    Oxford Science Enterprises3 shared
    Alumni Ventures2 shared

    Last updated: 7 October 2026